PTC Therapeutics Investor Relations Material
Latest events
Q4 2023
PTC Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from PTC Therapeutics Inc
Access all reports
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. The company's commercial product is Emflaza (deflazacort) used for the treatment of Duchenne muscular dystrophy in ambulatory patients aged 5 years and older. Its lead product candidate is Translarna that is completed Phase III clinical trials for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients; which has completed Phase II/III clinical trials for the treatment of cystic fibrosis; and that is under preclinical development stage for the treatment of myotonic dystrophy type 1.
Latest articles
Companies That Had Their IPO in 2023: Cautious Optimism
The cautiously optimistic market in 2023 saw stocks rebounded upwards, and interest in IPOs picked up from the previous year.
15 Apr 2024
Puig's 2024 IPO: Paco Rabanne, Jean Paul Gaultier, and Beyond
Explore Puig's journey from its 1914 inception to a 2024 IPO, showcasing its growth, strategic acquisitions, and impact in the beauty and fashion industry.
15 Apr 2024
Alphabet's Unstoppable Rise: From Stanford to Global Tech Leader
Discover Alphabet's rise from a university project to a global tech leader, highlighting its growth, diversification, and visionary leadership.
15 Apr 2024
Ticker symbol
Country
🇺🇸 United States